Literature DB >> 1563019

Ability of recombinant interferon gamma in vitro to restore the defective polymorphonuclear-cell- but not lymphocyte-mediated cytotoxic activities in patients with myelodysplastic syndromes.

G De Sanctis1, V Bottari, A Frezzolini, M Ficcardi, G De Rossi, M C Petti, F Mandelli, L Fontana.   

Abstract

In this study we analysed the in vitro effect of recombinant interferon gamma on cytotoxic activities mediated by both lymphoid and polymorphonuclear cells from 16 patients with myelodysplastic syndromes. Our results indicate the inability of interferon to restore the defective natural killer activity, natural killer cells and lectin-induced cytotoxicity. On the contrary we detected a boosting effect on the depressed polymorphonuclear cell cytotoxic activities. In our view, the ability of interferon to potentiate polymorphonuclear cell lytic efficiency could support an alternative defensive pathway against either neoplastic or infectious agents.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1563019     DOI: 10.1007/bf01741753

Source DB:  PubMed          Journal:  Cancer Immunol Immunother        ISSN: 0340-7004            Impact factor:   6.968


  31 in total

1.  Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group.

Authors:  J M Bennett; D Catovsky; M T Daniel; G Flandrin; D A Galton; H R Gralnick; C Sultan
Journal:  Ann Intern Med       Date:  1985-10       Impact factor: 25.391

Review 2.  Granulocyte function in myelodysplastic syndromes.

Authors:  P Ruutu
Journal:  Scand J Haematol Suppl       Date:  1986

3.  Interferon activation of "pre-spontaneous killer" (pre-SK) cells and alteration in kinetics of lysis of both "pre-SK" and active SK cells.

Authors:  S Targan; F Dorey
Journal:  J Immunol       Date:  1980-05       Impact factor: 5.422

4.  Lectin-dependent neutrophil-mediated cytotoxicity against chicken erythrocytes: a model of non-myeloperoxidase-mediated oxygen-dependent killing by human neutrophils.

Authors:  W H Greene; L Colclough; A Anton; R K Root
Journal:  J Immunol       Date:  1980-12       Impact factor: 5.422

Review 5.  Progress in the therapy of myelodysplastic syndromes.

Authors:  M A Boogaerts
Journal:  Blut       Date:  1989-06

6.  Deficiency of lymphocyte lectin-dependent cytotoxicity in myelodysplastic syndromes.

Authors:  L Fontana; G De Sanctis; G De Rossi; V Bottari; M C Petti; F Ensoli; D Pasqualetti; F Mandelli
Journal:  Acta Haematol       Date:  1989       Impact factor: 2.195

7.  Defective antibody-dependent and lectin-induced polymorphonuclear cytotoxicity in patients with myelodysplastic syndromes.

Authors:  L Fontana; G De Sanctis; V Bottari; M C Petti; F Mandelli
Journal:  Haematologica       Date:  1990 Jan-Feb       Impact factor: 9.941

8.  Tumor necrosis factor and immune interferon synergistically induce cytochrome b-245 heavy-chain gene expression and nicotinamide-adenine dinucleotide phosphate hydrogenase oxidase in human leukemic myeloid cells.

Authors:  M A Cassatella; L Hartman; B Perussia; G Trinchieri
Journal:  J Clin Invest       Date:  1989-05       Impact factor: 14.808

9.  Human natural killer cells can inhibit clonogenic growth of fresh leukemic cells.

Authors:  M Beran; M Hansson; R Kiessling
Journal:  Blood       Date:  1983-03       Impact factor: 22.113

10.  Immunoregulatory abnormalities in myelodysplastic disorders.

Authors:  M A Baumann; T J Milson; C W Patrick; J A Libnoch; R H Keller
Journal:  Am J Hematol       Date:  1986-05       Impact factor: 10.047

View more
  1 in total

1.  CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients.

Authors:  Li Yang; Fei Wang; Liping Wang; Lan Huang; Jing Wang; Bin Zhang; Yi Zhang
Journal:  Oncotarget       Date:  2015-04-30
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.